Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2005-01-04
2005-01-04
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S093710, C424S085200, C424S085700, C435S372000, C435S355000, C435S366000, C435S374000, C435S377000, C435S384000, C435S386000, C435S423000
Reexamination Certificate
active
06838081
ABSTRACT:
The present invention provides methods for enhancing the development of APC from precursor cells by administering a combination of GM-CSF and IL-4. The precursor cells include: cells contained in peripheral blood, CD14+cells and precursors in bone marrow. Thus, administration of GM-CSF and IL-4 can be used as a form of cytokine immunotherapy. One embodiment of the present invention involves systemic administration of GM-CSF and IL-4. In this embodiment, APC are required to directly access tumor antigens as they exist in vivo within the patient. A further embodiment of the present invention involves co-administration of a tumor-associated or tumor-specific antigen, with GM-CSF and IL-4, to induce antigen-specific immunity mediated by APC. Yet another embodiment of the present invention describes systemic administration of GM-CSF and IL-4 to achieve reduced tumor burden.
REFERENCES:
Romani et al. Immunological method 19965, vol. 196, pp. 137-151.*
Ambe et al S-100 Protein-positive dendritic cells in coloraectal adedenocarcinomas,Cancer63:496-503, 1989 (Exhibit 1).
Bachettis et al.: Transfer of gene for thymidine kinase-deficient human cells by purified herpes simplex viral DNA.PNAS USA, 1977 74:1590 (Exhibit 2).
Banchereau and Steinman, Dendritic cells and the control of immunity,Nature392:245, 1998 (Exhibit 3).
Becker Becker, Y., Anticancer role of dendritic cells (DC) in human and experimental cancers—A review,Anticancer Res. 1992, 12:511-520 (Exhibit 4).
Bernhard et al 1995Cancer Res.55:1099-1104 (Exhibit 5).
Bukowski et al 1993J. Immunoth.13:267-276 (Exhibit 6).
Caux et al., 1996,J. Exp. Medicine184:695-206 (Exhibit 7).
Chen et al 1994J. of Immunology153:4775-4787 (Exhibit 8).
Enk et al 1997Internat. J. Cancer73:309-316 (Exhibit 9).
Flamand et al 1994Eur. J. Immunol. 24:605-610 (Exhibit 10).
Freundenthal and Steinman 1990PNAS87:7698 (Exhibit 11).
Furukawa et 1985Cancer56:2651-2656 (Exhibit 12).
Galrilovich et al. 1997Clin. Cancer Res.3:483-490 (Exhibit 13).
Geller et al. an efficient deletion mutant packaging system for a defective herpes simplex virus vectors: Potential applications to human gene therapy and neuronal physiology.PNAS USA, 1990 87:8950 (Exhibit 14).
Ghosh et al 1993Eur. Cytokine Network4:205-211 (Exhibit 15).
Ghosh-Choudhury G, et al., Human adenovirus cloning vectors based on infectious bacterial plasmids.Gene1986; 50:161 (Exhibit 16).
Gilleece et al 1992Br. J. Cancer66:204-210 (Exhibit 17).
Grabbe et al 1995Immunology Today16:117-120 (Exhibit 18).
Gunji et al 1997Oncology54:69-73 (Exhibit 19).
Hock RA, et al., Retrovirus mediated transfer and expression of drug resistance genes in human hemopoietic progenitor cells.Nature1986; 320:275 (Exhibit 20).
Hsu et al 1996Nature Med.2:52-58 (Exhibit 21).
Huang et al 1994Science264:961-965 (Exhibit 22).
Ishigami et al 1998Oncology55:65-69 (Exhibit 23).
June et al 1994Immunol. Today15:321-331 (Exhibit 24).
Kaufman R.J.; identification of the component necessary for adenovirus translational control and their utilization in cDNA expression vectors.PNAS USA, 1985 82:689 (Exhibit 25).
Kiertscher and Roth 1996J Leukocyte Biol.59: 208-218 (Exhibit 26).
Lauener et al 1990Eur. J. Immunol.20:2375-2381 (Exhibit 27).
Markowicz et al 1990J. Clin. Investigation85:9955-961 (Exhibit 28).
Mayordomo et al 1995Nature Medicine1:1297-1302 (Exhibit 29).
Mehta-Damini et al 1994J Immunology153:996-1003 (Exhibit 30).
Modino and Jenkins 1994J. Leukocyte Biol.55:805-815 (Exhibit 31).
Morse et al 1997Ann. Surgery226:6-16 (Exhibit 32).
Morse et al., 1999Cancer Research59:56-58 (Exhibit 33).
Nestle et al 1998Nature Med.4:328-332 (Exhibit 34).
Ostrand-Rosenberg et al 1994Current Opinion in Immunology6:722-727 (Exhibit 35).
Peters et al 1993Adv. Exp. Med. Biol.329:275-280 (Exhibit 36).
Philips et al 1989Blood: 74:26-34 (Exhibit 37).
Ratta et al., 1998Br J. Haematology101:756-65 (Exhibit 38).
Romani et al 1994J. Exp. Med180:83-93 (Exhibit 39).
Rosenfeld M, et al., Adenovirus-mediated transfer of a recombinant α1-antitrypsin gene to the lung epithelium in vivo.Science1991; 252:431 (Exhibit 40).
Rosenzwajg et al., 1996,Blood87:535 (Exhibit 41).
Sallusto et al 1994J. Exp. Med.179: 1109-1118 (Exhibit 42).
Sarver N, et al., Bovine papilloma virus DNA: A novel eukaryotic cloning vector.Mol Cell Biol1981; 1:486 (Exhibit 43).
Schroder et al 1988Am J. Clin. Path.89:295-300 (Exhibit 44).
Smith et al. infectious vaccinia virus recombinants that express hepatitis B virus surface antigens.Nature, 1983 302:490 (Exhibit 45).
Tao and Levy 1993Nature362:755-758 (Exhibit 46).
Thomas and Lipsky 1994J. Immunol.153:4016-4027 (Exhibit 47).
Troy et al 1998Clin. Cancer Res.4:585-593 (Exhibit 48).
Wakimoto et al 1996Cancer Research56:1828-1833 (Exhibit 49).
Zhou and Tedder, 1996PNAS93:2588-92 (Exhibit 50).
Panicali D, et al., Construction of pox virus as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccine virus.Proc Natl Acad Sci USA1982; 79:4927 (Exhibit 52).
Young et al 1992J. Clin. Invest.90:229-237 9 (Exhibit 52).
Hart 1997,Blood90:3245 (Exhibit 53).
Guild B, et al., Development of retrovirus vectors useful for expressing genes in cultured murine embryonic cells and hematopoietic cells in vivo.J Virol1988; 62:3795-3801 (Exhibit 54).
Atkinson et al. In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood. Mar. 15, 1991, vol. 77, No. 6, pp. 1376-1382. (Exhibit 55).
Berkner, K.L.: Development of adenovirus vectors for expression of heterologous genes.Biotechniques, 1988 6:616-624. (Exhibit 56).
Gillies, SD et al. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. 1993Bioconj. Chem.May-Jun.; 4:230-235. (Exhibit 57).
Iscove et al., Presursors (pre-CFCmulti) of multilineage hemopoietic colony-forming cells quantitated in vitro. The Journal of Immunology. Jul. 1, 1990, vol. 145, No. 1, pp. 190-195. (Exhibit 58).
Murphy et al. Phase I Clinical Trial: T-Cell Therapy for Prostate Cancer Using Autologous Dendritic Cells Pulsed With HLA-A0201-Specific Peptides from Prostate-Specific Membrane Antigen; 1996Prostate29:371-380. (Exhibit 59).
O'garra et al. The BCL1 B lymphoma responds to IL-4, IL-5, and GM-CSF. Cellular Immunology. 1989, vol. 123, pp. 189-200 (Exhibit 60).
Tepper et al., Experimental and clinical studies of cytokine gene-modified tumor cells. Human Gene Therapy. 1994, vol. 5, pp. 153-164. (Exhibit 61).
Figlin Robert Alan
Gitlitz Barbara Jennifer
Kiertscher Sylvia Marie
Roth Michael Derek
Housel James
Li Baoqun
Mandel & Adriano
The Regents of the University of California
LandOfFree
Methods for enhancing antigen-presenting cells and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for enhancing antigen-presenting cells and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for enhancing antigen-presenting cells and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3429739